Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities: 2014-2025

Historic Other financing activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Sep 2025 value amounting to $209,000.

  • Viridian Therapeutics, Inc.\DE's Other financing activities fell 98.47% to $209,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year decrease of 256.45%. This contributed to the annual value of $446,000 for FY2022, which is N/A change from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Other financing activities of $209,000 as of Q3 2025, which was up 0.97% from $207,000 recorded in Q1 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Other financing activities ranged from a high of $18.1 million in Q3 2022 and a low of -$24.1 million during Q4 2024.
  • Moreover, its 2-year median value for Other financing activities was $208,000 (2025), whereas its average is $69,333.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Other financing activities in the last 5 years was 4,491.82% (2021), contrasted with its biggest fall of 247.51% (2021).
  • Over the past 4 years, Viridian Therapeutics, Inc.\DE's Other financing activities (Quarterly) stood at -$5.3 million in 2021, then crashed by 235.93% to -$17.7 million in 2022, then reached -$24.1 million in 2024, then tumbled by 98.47% to $209,000 in 2025.
  • Its last three reported values are $209,000 in Q3 2025, $207,000 for Q1 2025, and -$24.1 million during Q4 2024.